108.44
price down icon0.60%   -0.65
after-market Dopo l'orario di chiusura: 108.20 -0.24 -0.22%
loading
Precedente Chiudi:
$109.09
Aprire:
$109.115
Volume 24 ore:
4.59M
Relative Volume:
0.50
Capitalizzazione di mercato:
$134.89B
Reddito:
$28.73B
Utile/perdita netta:
$5.97B
Rapporto P/E:
22.83
EPS:
4.75
Flusso di cassa netto:
$9.84B
1 W Prestazione:
+0.67%
1M Prestazione:
+1.97%
6M Prestazione:
+17.35%
1 anno Prestazione:
+69.60%
Intervallo 1D:
Value
$107.23
$109.45
Intervallo di 1 settimana:
Value
$105.58
$109.55
Portata 52W:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
108.44 134.00B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
719.39 650.81B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.43 368.56B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
183.09 321.13B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.87 222.75B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.60 303.04B 43.59B 15.04B 10.74B 3.3766

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
11:31 AM

Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire

11:31 AM
pulisher
May 27, 2025

Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria

May 27, 2025
pulisher
May 26, 2025

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

Gilead Ready To Go After Hepatitis D Again - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha

May 26, 2025
pulisher
May 26, 2025

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena

May 26, 2025
pulisher
May 25, 2025

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN

May 25, 2025
pulisher
May 24, 2025

Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter

May 24, 2025
pulisher
May 24, 2025

Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance

May 24, 2025
pulisher
May 23, 2025

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus

May 23, 2025
pulisher
May 23, 2025

After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider

May 23, 2025
pulisher
May 23, 2025

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire

May 23, 2025
pulisher
May 23, 2025

Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma

May 23, 2025
pulisher
May 22, 2025

Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech

May 22, 2025
pulisher
May 22, 2025

Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks

May 22, 2025
pulisher
May 21, 2025

What Analysts Are Saying About Gilead Sciences Stock - Benzinga

May 21, 2025
pulisher
May 21, 2025

Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire

May 21, 2025
pulisher
May 21, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? - Zacks Investment Research

May 20, 2025
pulisher
May 20, 2025

Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 10 - 3BL Media

May 20, 2025
pulisher
May 19, 2025

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

May 19, 2025
pulisher
May 19, 2025

Unusual Options Alert: The Smart Money Is Piling Into Gilead Sciences (GILD) - Barchart.com

May 19, 2025
pulisher
May 19, 2025

Gilead Sciences: Buy Rating Affirmed Amid Promising Lenacapavir Approval and Market Expansion - TipRanks

May 19, 2025
pulisher
May 19, 2025

Gilead Sciences discovers new PRMT5 inhibitors - BioWorld MedTech

May 19, 2025
pulisher
May 18, 2025

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance

May 18, 2025
pulisher
May 16, 2025

Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Gilead Sciences (GILD) is Flashing a Quant Signal That Wall Street is Ignoring - Money Morning

May 16, 2025
pulisher
May 16, 2025

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories - CSRwire

May 16, 2025
pulisher
May 15, 2025

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and E - BioSpace

May 15, 2025
pulisher
May 15, 2025

Does Gilead's drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals

May 15, 2025
pulisher
May 15, 2025

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Gilead And Kite Announce Presentation Of Transformative Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Does Gilead's latest PreP drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals

May 15, 2025
pulisher
May 15, 2025

Upcoming Meeting for GILD in Foster City | GILD Stock News - GuruFocus

May 15, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general PFE
$23.18
price down icon 1.82%
$278.40
price down icon 0.38%
drug_manufacturers_general GSK
$39.18
price down icon 0.66%
drug_manufacturers_general MRK
$76.17
price down icon 1.83%
drug_manufacturers_general NVO
$68.60
price down icon 2.61%
Capitalizzazione:     |  Volume (24 ore):